Liquidia Corp (OQ:LQDA)

Apr 02, 2024 09:00 am ET
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, and Micheal Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an overview and update on the...
Apr 01, 2024 06:00 am ET
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that on March 28, Judge Andrews of the U.S. District Court for the District of Delaware (District Court) has set aside the injunction that was issued in August 2022 in...
Mar 13, 2024 06:00 am ET
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the full year ended December 31, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the 2023 financial results and provide a corporate...
Mar 06, 2024 06:30 am ET
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2023 financial results on Wednesday, March 13, 2024. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a...
Jan 30, 2024 06:30 am ET
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today announced that the Company will present data from the L606 clinical program at the Pulmonary Vascular Research Institute (PVRI) 2024 Annual Congress to be held January 31 through...
Jan 25, 2024 06:00 am ET
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) provided an update on its review of the New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary...
Jan 19, 2024 06:30 am ET
Liquidia Corporation Announces Updates to Operations Leadership
Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today updates and promotions to its operations leadership in advance of the potential approval and launch of YUTREPIA™ (treprostinil) inhalation powder. Michael Kaseta, Chief...
Jan 08, 2024 08:22 am ET
Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today it filed its answer, affirmative defenses and a partial motion to dismiss in response to the amended patent infringement complaint filed by United Therapeutics...
Jan 05, 2024 06:45 am ET
Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) provided an update today on the clinical progress of its pipeline programs to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung...
Jan 04, 2024 09:10 am ET
Liquidia Corporation Announces $100 Million in New Financings
Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that the Company has entered into agreements for an additional $100 million in capital between two transactions with funds associated with Patient Square Capital and...
Jan 02, 2024 06:45 am ET
Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, beginning at...
Dec 20, 2023 04:56 pm ET
U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)
Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced that the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) today affirmed the earlier decision by the Patent Trial and Appeal Board (PTAB) which found all claims...
Dec 12, 2023 07:13 am ET
Liquidia Announces Pricing of Public Offering of Common Stock
Liquidia Corporation (NASDAQ: LQDA) announced today that it has priced an underwritten public offering of 3,491,620 shares of common stock at a public offering price of $7.16 for total gross proceeds of approximately $25.0 million, before deducting...
Nov 07, 2023 06:30 am ET
Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the third quarter ended September 30, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate...
Oct 31, 2023 06:30 am ET
Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023
Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a...
Oct 02, 2023 07:00 am ET
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent’s 2024 Annual Meeting of Stockholders. Both joined...
Sep 25, 2023 04:09 pm ET
FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label
Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Company’s amendment to the tentatively approved new drug application (NDA) for YUTREPIA™ (treprostinil)...
Sep 06, 2023 04:30 pm ET
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office
Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company), announced today that United Therapeutics Corporation (UTHR) filed a patent infringement action under the Hatch-Waxman Act in the U.S. District Court for the District of Delaware...
Aug 10, 2023 06:00 am ET
Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the second quarter ended June 30, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate...
Aug 03, 2023 08:17 am ET
Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023
Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2023 financial results on Thursday, August 10, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a...
Jul 27, 2023 06:00 am ET
Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder
Liquidia Corporation (NASDAQ: LQDA) announced today the submission of an amendment to the tentatively approved new drug application (NDA) for YUTREPIA™ (treprostinil) inhalation powder to add the treatment of pulmonary hypertension associated with...
Jul 24, 2023 01:46 pm ET
U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation
Liquidia Corporation (NASDAQ: LQDA) announced today that the Court of Appeals for the Federal Circuit (Federal Circuit) has affirmed all rulings by the United States District Court for the District of Delaware (District Court) in litigation filed...
Jun 28, 2023 05:36 am ET
Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America
Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) and Pharmosa Biopharm (Pharmosa) today announced that they have entered into an exclusive licensing agreement for the development and commercialization in North America of L606, an...
May 31, 2023 06:30 am ET
Liquidia Corporation to Present at the 2023 Jefferies Healthcare Conference
Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that Mr. Roger Jeffs, Chief Executive Officer, and Mr. Michael Kaseta, Chief Financial Officer, will provide an update on the Company's business during a fireside chat at the 2023...
May 19, 2023 06:15 am ET
Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the Company will present data related to the investigational use of YUTREPIA™ (treprostinil) inhalation powder at the 2023 American Thoracic Society (ATS)...
May 04, 2023 06:30 am ET
Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update
Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the first quarter ended March 31, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate...
May 02, 2023 06:45 am ET
Liquidia Corporation to Present at BofA Securities 2023 Health Care Conference
Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer, will provide an update on the company's business during a fireside chat at the BofA Securities 2023 Health Care Conference in Las Vegas, Nevada....
Apr 27, 2023 06:45 am ET
Liquidia Corporation to Report First Quarter 2023 Financial Results on May 4, 2023
Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2023 financial results on Thursday, May 4, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a...
Apr 11, 2023 06:45 am ET
Liquidia Corporation to Present at 22nd Annual Needham Virtual Healthcare Conference
Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer, will provide an overview and update on the company's business during a fireside chat session at the 22nd Annual Needham Virtual Healthcare...
Apr 03, 2023 06:45 am ET
Liquidia and GSK Restructure License to PRINT Technology for Inhaled Applications
Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that it has entered a new, non-exclusive license agreement with GSK to enable pre-clinical research of inhaled formulations of GSK’s molecules based upon Liquidia’s...
Mar 16, 2023 06:30 am ET
Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the full year ended December 31, 2022. The Company will host a webcast at 8:30 a.m. ET to discuss the 2022 financial results and provide a...
Mar 09, 2023 07:19 am ET
Liquidia Corporation to Report Full Year 2022 Financial Results on Thursday, March 16, 2023
Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2022 financial results on Thursday, March 16, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate...
Feb 02, 2023 04:39 pm ET
Patent Trial and Appeal Board (PTAB) Reaffirms Decision to Invalidate All Claims of United Therapeutics (UTHR) Patent No. 10,716,793 (‘793 Patent)
Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced that the PTAB has reaffirmed its original decision in the ‘793 IPR, which found all claims of the ‘793 patent to be unpatentable due to the existence of known prior art cited...
Feb 02, 2023 06:30 am ET
Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 10,000 shares of Liquidia’s common stock to newly hired non-executive employees under the Liquidia Corporation 2022 Inducement...
Jan 09, 2023 06:30 am ET
Liquidia Enters Into a Revenue Interest Financing Agreement With HealthCare Royalty for Up to $100 Million
Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that it has entered into a Revenue Interest Financing Agreement with HealthCare Royalty (HCRx) for a total investment amount of up to $100 million. Liquidia intends to...
Dec 05, 2022 04:05 pm ET
Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH)
Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today a collaboration with Sandoz Inc. (Sandoz) and Mainbridge Health Partners LLC (Mainbridge) to support the development of a new subcutaneous pump for infusion of...
Nov 08, 2022 06:30 am ET
Liquidia Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the third quarter ended September 30, 2022. The Company will host a webcast and conference call at 8:30 a.m. ET to discuss the third quarter 2022...
Nov 02, 2022 10:15 am ET
ANAVASI DIAGNOSTICS ANNOUNCES NEWLY ELECTED OUTSIDE BOARD OF DIRECTORS
The New Board Members Will Bring Industry Experience to Contribute to Company Growth
Nov 01, 2022 06:45 am ET
Liquidia to Report Third Quarter 2022 Financial Results on November 8, 2022
Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial...
Oct 27, 2022 04:10 pm ET
Precedential Opinion Panel Denies United Therapeutics’ Request for Review of ‘793 Inter Partes Review Decision
Liquidia Corporation (NASDAQ: LQDA) announced today that on October 26, 2022, the Precedential Opinion Panel (POP) of the United States Patent and Trademark Office (USPTO) denied a request by United Therapeutics (UTC) to review the decision by the...
Oct 17, 2022 06:30 am ET
Liquidia Announces Presentations at the CHEST 2022 Annual Meeting
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the presentation of data related to the investigational use of YUTREPIA™ (treprostinil) inhalation powder, previously referred to as LIQ861, at the CHEST 2022 Annual...
Aug 31, 2022 07:46 pm ET
Liquidia Provides Update on Hatch-Waxman Litigation and to Host Call on September 1, 2022, at 8:00am E.T.
Liquidia Corporation (NASDAQ: LQDA) announced today that a ruling was issued by Judge Andrews, who is presiding over the litigation filed by United Therapeutics Corporation (UTC) in the United States District Court for the District of Delaware...
Aug 22, 2022 07:00 am ET
Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 7,000 shares of Liquidia’s common stock to newly hired non-executive employees under the Liquidia Corporation 2022 Inducement...
Aug 15, 2022 09:37 am ET
Thinking about buying stock in Ironsource, Helbiz, Liquidia, Twin Vee Powercats, or Aquestive Therapeutics?
NEW YORK, Aug. 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IS, HLBZ, LQDA, VEEE, and AQST.
Aug 11, 2022 06:45 am ET
Liquidia Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the second quarter ended June 30, 2022. The Company will host a webcast and conference call at 8:30 a.m. ET to discuss the second quarter 2022...
Aug 04, 2022 08:18 am ET
Liquidia to Report Second Quarter 2022 Financial Results on August 11, 2022
Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2022 financial results on Thursday, August 11, 2022. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial...
Aug 01, 2022 07:46 am ET
Liquidia Announces the Publication of Long-Term Clinical Data from Completed INSPIRE Study in the Journal Pulmonary Circulation
Liquidia Corporation (NASDAQ: LQDA) announced today the publication of clinical data from the completed INSPIRE study evaluating YUTREPIA™ (treprostinil) inhalation powder, formerly known as LIQ861, in patients with pulmonary arterial hypertension...
Aug 01, 2022 06:24 am ET
Liquidia to Participate in Upcoming Investor Conferences
Liquidia Corporation (NASDAQ: LQDA) announced today that it will be participating at the following investor conferences next week: BTIG Biotechnology Conference 2022Date: Monday, August 8, 2022Location: Hybrid Event at St. Regis Hotel, New York,...
Jul 25, 2022 08:51 am ET
Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for 2,000 shares of Liquidia’s common stock to a newly hired non-executive employee under the Liquidia Corporation 2022 Inducement Plan (the...
Jul 21, 2022 04:30 pm ET
Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Liquidia Corporation (NASDAQ: LQDA) today announced that, in connection with the previously announced appointment of Rajeev Saggar, M.D., Liquidia’s new Chief Medical Officer, it has agreed to grant him an employment inducement equity award. As...
Jul 19, 2022 04:30 pm ET
Liquidia Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent
Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) ruled in its favor in the Inter Partes Review (IPR) proceeding against U.S. Patent No. 10,716,793 (‘793 patent) owned by United Therapeutics...
Jun 27, 2022 06:26 am ET
Liquidia Corporation Added to Russell 2000® and 3000® Indexes
Liquidia Corporation (NASDAQ: LQDA) announced today that the company was added as a member of the US small-cap Russell 2000® Index, effective after the US market opens on June 27, as part of the 2022 Russell indexes reconstitution. Membership in...
Jun 24, 2022 04:15 pm ET
Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 24,800 shares of Liquidia’s common stock to newly hired non-executive employees under the Liquidia Corporation 2022 Inducement...
Jun 24, 2022 09:35 am ET
Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for 2,000 shares of Liquidia’s common stock to a newly hired non-executive employee under the Liquidia Corporation 2022 Inducement Plan (the...
Jun 20, 2022 07:00 am ET
Liquidia Appoints Rajeev Saggar, M.D., as Chief Medical Officer
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the appointment of Rajeev Saggar, M.D., to the position of Chief Medical Officer. In this role, Dr. Saggar will oversee all aspects of research, clinical development,...
Jun 09, 2022 04:30 pm ET
Liquidia Announces Presentation at the 2022 Pulmonary Hypertension Association (PHA) International Conference
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the presentation of data related to the investigational use of YUTREPIA™ (treprostinil) inhalation powder, previously referred to as LIQ861, at the Pulmonary...
Jun 07, 2022 04:30 pm ET
Update to Liquidia’s Participation in the Jefferies Healthcare Conference
Liquidia Corporation (NASDAQ: LQDA) announced today an update to the company’s participation in the Jefferies Healthcare Conference. Mr. Michael Kaseta, Chief Financial Officer, will participate in a fireside chat on Thursday, June 9, 2022, now...
Jun 02, 2022 09:03 am ET
Liquidia to Participate in the Jefferies Healthcare Conference
Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 11:00 am Eastern Time. The conference is...
May 26, 2022 08:30 am ET
Thinking about buying stock in Macy's, Destination XL, Liquidia, IQIYI, or Joby Aviation?
NEW YORK, May 26, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for M, DXLG, LQDA, IQ, and JOBY.
May 16, 2022 07:30 am ET
Liquidia Announces Presentations at the 2022 American Thoracic Society (ATS) International Conference
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the presentation of data related to the investigational use of YUTREPIA™ (treprostinil) inhalation powder, previously referred to as LIQ861, at the America Thoracic...
May 12, 2022 07:00 am ET
Liquidia Reports First Quarter 2022 Financial Results and Provides Corporate Update
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the first quarter ended March 31, 2022. The Company will host a webcast and conference call at 8:30 a.m. ET to discuss the first quarter 2022...
May 05, 2022 08:00 am ET
Liquidia to Report First Quarter 2022 Financial Results on May 12, 2022
Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2022 financial results on Thursday, May 12, 2022. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results...
Apr 25, 2022 08:45 am ET
Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 35,700 shares of Liquidia’s common stock to newly hired non-executive employees under the Liquidia Corporation 2022 Inducement...
Apr 20, 2022 10:01 am ET
Liquidia Announces Oral Presentation at the 42nd Annual Meeting of International Society for Heart and Lung Transplant (ISHLT)
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Sandeep Sahay, MD, from Houston Methodist Hospital will present clinical data from studies of YUTREPIA™ (treprostinil) inhalation powder, previously referred to...
Apr 18, 2022 04:05 pm ET
Liquidia Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment Option
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia”) today announced the closing of its previously announced underwritten public offering of 11,274,510 shares of its common stock, which includes full exercise of the underwriters’ over-allotment option...
Apr 12, 2022 09:38 pm ET
Liquidia Announces Pricing of Public Offering of Common Stock
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia”) announced the pricing of an underwritten public offering of 9,803,922 shares of its common stock at a public offering price of $5.10, for total gross proceeds of approximately $50.0 million, before...
Apr 12, 2022 04:17 pm ET
Liquidia Announces Proposed Offering of Common Stock
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia”) announced today that it has commenced an underwritten public offering of its common stock. All of the shares in the proposed offering will be sold by Liquidia. In addition, Liquidia expects to grant...
Mar 22, 2022 04:30 pm ET
Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for an aggregate of 2,000 shares of Liquidia’s common stock to a newly hired non-executive employee under the Liquidia Corporation 2022...
Mar 17, 2022 06:30 am ET
Liquidia Corporation Reports Full-Year 2021 Financial Results and Provides Corporate Update
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for full-year ended December 31, 2021. The Company will host a webcast and conference call at 8:30 a.m. ET to discuss the 2021 financial results and...
Mar 10, 2022 07:00 am ET
Liquidia Corporation to Report Full Year 2021 Financial Results on Thursday, March 17, 2022
Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2021 financial results on Thursday, March 17, 2022. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and...
Mar 01, 2022 05:22 am ET
Pathalys Pharma, Inc. Launches with Mission to Address High Priority Needs in Chronic Kidney Disease
RESEARCH TRIANGLE PARK, N.C., March 1, 2022 /PRNewswire/ -- Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range of best-in-class therapies for patients with chronic kidney disease (CKD), today announced its formation made possible through initial seed financing from DaVita Venture Group, part of DaVita Inc. (NYSE: DVA), and Catalys Pacific. Pathalys launches with a novel clinical-stage asset, upacicalcet, that was acquired through a license granted by EAPharma for exclusive rights to the development and commercializatio
Feb 23, 2022 06:30 am ET
Liquidia Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for an aggregate of 25,700 shares of Liquidia’s common stock to a newly hired non-executive employee under the Liquidia Corporation 2022...
Jan 07, 2022 09:02 am ET
Liquidia Re-Finances Debt Facility With Silicon Valley Bank To Increase To $40.0 Million
Liquidia Corporation (NASDAQ: LQDA) announced today the closing of a debt facility on January 7, 2022, with Silicon Valley Bank (SVB) which provides Liquidia with up to $40.0 million in term loans of which the first $20.0 million was funded at...
Jan 03, 2022 04:52 pm ET
Liquidia Corporation Announces Chief Executive Officer Transition
Liquidia Corporation (NASDAQ: LQDA) today announced Dr. Roger Jeffs has been appointed as Chief Executive Officer (CEO) effective January 3, 2022 and will continue as a director on the board. He succeeds Damian deGoa who will remain a director of...
Dec 29, 2021 06:45 am ET
Stipulation of Partial Judgment In Favor of Liquidia Filed In Hatch-Waxman Litigation
Liquidia Corporation (NASDAQ: LQDA) announced today that United Therapeutics Corporation (UTC) has filed a stipulation of partial judgment with respect to U.S. Patent No. 9,604,901 (‘901 patent) in the on-going litigation under the Hatch-Waxman Act...
Nov 11, 2021 04:30 pm ET
Liquidia to Participate in the Jefferies London Healthcare Conference
Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer of Liquidia, will provide an update on the company's business during a fireside chat at the Jefferies 2021 Virtual London Healthcare Conference...
Nov 08, 2021 05:45 am ET
FDA Grants Tentative Approval for Liquidia’s YUTREPIA™ (Treprostinil) Inhalation Powder
Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder, previously referred to as LIQ861. YUTREPIA is indicated for the...
Nov 03, 2021 04:55 pm ET
Liquidia Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the quarter and nine-months ended September 30, 2021. Damian deGoa, Liquidia’s Chief Executive Officer, said: “We had another productive...
Oct 08, 2021 05:23 pm ET
Liquidia Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent
Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) ruled in its favor in the Inter Partes Review (IPR) proceeding against U.S. Patent No. 9,604,901 (‘901 patent) owned by United Therapeutics...
Sep 10, 2021 08:29 am ET
Liquidia to Participate at H.C. Wainwright 23rd Annual Global Investment Conference
Liquidia Corporation (NASDAQ: LQDA) announced today that Damian deGoa, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference, which runs from September 13 – 15, 2021. The conference will be held in a...
Aug 18, 2021 04:15 pm ET
FDA Completes On-site Pre-Approval Inspection of Liquidia’s Morrisville, North Carolina Facility
Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has completed an on-site Pre-Approval Inspection (PAI) of its Morrisville, North Carolina facility in connection with the on-going review of the...
Aug 12, 2021 08:00 am ET
U.S. Patent Trial and Trademark Appeal Board Decides to Institute Inter Partes Review of United Therapeutics’ Tyvaso® Patent
Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR) against U.S. Patent No. 10,716,793 (‘793 patent), owned by United Therapeutics Corporation (UTC) and...
Aug 10, 2021 07:00 am ET
Liquidia Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the quarter ended June 30, 2021. The Company will host a webcast and conference call at 8:30 a.m. Eastern Daylight Time to discuss the second...
Aug 03, 2021 07:00 am ET
Liquidia to Report Second Quarter 2021 Financial Results on August 10, 2021
Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2021 financial results on Tuesday, August 10, 2021. The company will host a webcast and conference call at 8:30 a.m. Eastern Daylight Time to discuss...
Jun 02, 2021 07:00 am ET
Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder
Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for LIQ861 (treprostinil) inhalation powder to treat pulmonary arterial hypertension...
May 26, 2021 07:00 am ET
Liquidia Corporation To Present At The Jefferies Virtual Healthcare Conference
Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia, will provide an overview and update on the company's business during a fireside chat session at the Jefferies Virtual Healthcare...
May 24, 2021 04:05 pm ET
Liquidia Announces Generic Treprostinil Injection Now Also Available for Subcutaneous Route of Administration
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Sandoz Treprostinil Injection, a generic form of Remodulin®, is now also available for subcutaneous (“SC”) administration to treat patients diagnosed with...
May 13, 2021 07:00 am ET
Liquidia Reports First Quarter 2021 Financial Results and Provides Corporate Update
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the quarter ended March 31, 2021. The Company will host a webcast and conference call at 8:30 a.m. ET to discuss the first quarter financial...
May 10, 2021 06:30 am ET
Liquidia Resubmits New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension
Liquidia Corporation (NASDAQ: LQDA) announced today that on May 7, 2021, it resubmitted its New Drug Application (NDA) for LIQ861 for the treatment of pulmonary arterial hypertension (PAH). The U.S. Food and Drug Administration (FDA) issued a...
May 06, 2021 07:00 am ET
Liquidia Corporation to Report First Quarter 2021 Financial Results on May 13, 2021
Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2021 financial results on Thursday, May 13, 2021. The company will host a webcast and conference call at 8:30 a.m. Eastern Daylight Time to discuss financial...
Apr 13, 2021 07:00 am ET
Liquidia Corporation Announces $21.7 Million Private Placement
Liquidia Corporation (NASDAQ: LQDA) announced today that it has entered into a common stock purchase agreement with certain institutional, accredited investors for the private placement of 8,626,037 shares of common stock at a purchase price of...
Apr 07, 2021 07:00 am ET
Liquidia Corporation To Present At The 20th Annual Needham Virtual Healthcare Conference
Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia, will provide an overview and update on the company's business during a fireside chat session at the 20th Annual Needham Virtual...
Mar 30, 2021 07:00 am ET
Liquidia Announces Generic Treprostinil Injection Will Be Available for Subcutaneous Route of Administration
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Treprostinil Injection, a generic form of Remodulin®, will soon be available for subcutaneous (“SC”) administration to treat patients diagnosed with pulmonary...
Mar 23, 2021 07:00 am ET
Liquidia Corporation Reports Full-Year 2020 Financial Results and Provides Corporate Update
Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the full-year ended December 31, 2020. The Company will host a webcast and conference call at 8:30 a.m. ET to discuss the 2020 financial results...
Mar 09, 2021 07:30 am ET
Liquidia Corporation to Host 2020 Financial Results Conference Call on March 23, 2021
Liquidia Corporation (NASDAQ: LQDA) today announced that 2020 financial results will be reported on Tuesday, March 23, 2021. The company will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and provide a corporate...
Mar 02, 2021 08:30 am ET
Liquidia Corporation Secures $20.5 Million Debt Facility with Silicon Valley Bank
Liquidia Corporation (NASDAQ: LQDA) today announced the closing of a debt facility on February 26, 2021, with Silicon Valley Bank, which provides Liquidia with up to $20.5 million in term loans of which the first $10.5 million was funded at...
Jan 04, 2021 03:11 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Liquidia Corporation and Encourages Investors with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Liquidia Corporation (“Liquidia” or “the Company”) (NASDAQ:
Dec 31, 2020 04:21 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Liquidia Corporation and Encourages Investors with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Liquidia Corporation (“Liquidia” or “the Company”) (NASDAQ:
Dec 31, 2020 12:47 pm ET
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Announces Investigation of Securities Claims Against Liquidia Corporation – LQDA
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Liquidia Corporation (NASDAQ: LQDA) resulting from allegations that Liquidia may have issued materially misleading business information to the investing public.
Dec 20, 2020 12:05 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980....
Dec 14, 2020 09:28 am ET
Liquidia Corporation Announces Chief Executive Officer Transition
Liquidia Corporation (NASDAQ: LQDA) today announced Damian deGoa has been appointed as Chief Executive Officer (CEO) and a director of the Company, effective immediately. He succeeds Neal F. Fowler who has retired as CEO and a director of the...
Dec 12, 2020 08:13 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980....
Dec 07, 2020 08:21 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Nov 30, 2020 08:55 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Liquidia Corporation – LQDA
Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Nov 30, 2020 08:49 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Nov 30, 2020 07:15 am ET
Liquidia Corporation Appoints Michael Kaseta Chief Financial Officer
Liquidia Corporation (NASDAQ: LQDA) today announced Michael Kaseta has been appointed Chief Financial Officer (CFO), effective immediately. He succeeds Steve Bariahtaris who has served as Liquidia’s interim CFO since August 2020. Mr. Bariahtaris...
Nov 25, 2020 10:10 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
NEW YORK, Nov. 25, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Nov 25, 2020 07:00 am ET
Liquidia Receives Complete Response Letter from FDA for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension
Liquidia Technologies, Inc., a wholly owned subsidiary of Liquidia Corporation (NASDAQ: LQDA), today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the company’s New Drug Application (NDA)...
Nov 18, 2020 04:01 pm ET
Liquidia Closes Acquisition of RareGen
Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that it has closed the...
Nov 16, 2020 07:15 am ET
Liquidia Announces Results of Special Meeting of Stockholders
Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that its stockholders voted to...
Nov 12, 2020 10:06 am ET
Liquidia to Present at the 2020 Jefferies Virtual London Healthcare Conference
Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal Fowler, Chief...
Nov 09, 2020 07:15 am ET
Liquidia Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today reported financial results for the third...
Nov 02, 2020 07:15 am ET
Liquidia Reschedules Special Meeting of Stockholders and Reaffirms Recommendation to Approve Proposed Acquisition of RareGen, LLC
Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced it has rescheduled its special...
Oct 30, 2020 08:39 pm ET
UPDATE – Liquidia to Report Third Quarter 2020 Financial Results and Provide Corporate Update on November 6, 2020
Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that third quarter 2020 financial...
Oct 30, 2020 04:15 pm ET
Liquidia to Report Third Quarter 2020 Financial Results and Provide Corporate Update on November 6, 2020
Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that third quarter 2020 financial...
Oct 19, 2020 08:30 am ET
Liquidia Announces Postponement of Special Meeting of Stockholders
Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that it has postponed the...
Oct 14, 2020 09:25 am ET
Liquidia Provides Update on U.S. Patent Trial and Appeal Board Decision on Inter Partes Review of Two United Therapeutics’ Tyvaso® Patents
Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that the U.S. Patent Trial and...
Oct 05, 2020 07:15 am ET
Liquidia Names Gerald M. O’Brien, MD, as Vice President, Pulmonary Clinical Development
Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced the appointment of Dr. Gerald M....
Sep 17, 2020 07:15 am ET
Liquidia Announces Special Meeting Date to Approve Proposed Acquisition of RareGen, LLC
Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that the special meeting of its...
Aug 28, 2020 07:15 am ET
Liquidia Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treating Pulmonary Hypertension with Dry Powder Treprostinil
Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that it has received a Notice of...
Aug 20, 2020 09:15 am ET
Liquidia Announces Chief Financial Officer Transition
Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced Steven Bariahtaris has been...
Aug 10, 2020 07:15 am ET
Liquidia Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today reported financial results for the second...
Aug 05, 2020 05:30 pm ET
Liquidia to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal Fowler, Chief...
Aug 05, 2020 07:15 am ET
Liquidia Releases Exploratory Endpoint Data from INSPIRE Study at the American Thoracic Society (ATS) Annual Meeting
Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, announced that exploratory endpoint data from...
Aug 03, 2020 09:20 am ET
Liquidia to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020
Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that second quarter 2020...
Jul 24, 2020 09:08 am ET
Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of New Tyvaso Patent
Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that United Therapeutics...
Jul 08, 2020 10:35 pm ET
SHAREHOLDER ALERT: Halper Sadeh LLP Announces It is Investigating Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm
NEW YORK, July 8, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating whether the following mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders:
Jul 02, 2020 04:01 pm ET
Liquidia Announces Closing of Public Offering of Common Stock
Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, announced the closing of its previously...
Jun 29, 2020 10:45 pm ET
Liquidia to Host Conference Call to Provide Update on Recent Announcements
Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, will host a webcast and conference call on June...
Jun 29, 2020 10:30 pm ET
Liquidia Announces Pricing of Public Offering of Common Stock
Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, announced the pricing of an underwritten public...
Jun 29, 2020 04:05 pm ET
Liquidia Announces Proposed Offering of Common Stock
Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, announced today that it has commenced an...
Jun 29, 2020 04:01 pm ET
Liquidia to Acquire RareGen, LLC, and Expand Presence in PAH
Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, announced it has entered into a definitive...
Jun 05, 2020 03:30 pm ET
Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of Tyvaso Patents
Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that United Therapeutics...
May 27, 2020 08:04 pm ET
Liquidia to Present at the Jefferies Virtual Healthcare Conference
Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal Fowler, Chief...
May 18, 2020 07:15 am ET
Liquidia Appoints Tushar Shah, M.D., as Chief Medical Officer
Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced the appointment of Tushar...
May 11, 2020 04:01 pm ET
Liquidia Reports First Quarter 2020 Financial Results and Provides Corporate Update
Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today reported financial results for the first...
May 06, 2020 06:30 pm ET
Liquidia to Report First Quarter 2020 Financial Results and Provide Corporate Update on May 11, 2020
Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that first quarter 2020 financial...
Apr 30, 2020 07:30 am ET
Liquidia Releases Final LIQ861 Results from Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension
Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that it has released final...
Apr 09, 2020 07:30 am ET
Liquidia to Present at the 19th Annual Needham Healthcare Conference
Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal Fowler, Chief...
Apr 08, 2020 07:45 am ET
Liquidia Announces FDA Acceptance of New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension
Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that the U.S. Food and Drug...
Mar 11, 2020 07:00 am ET
Liquidia Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today reported...
Feb 26, 2020 04:30 pm ET
Liquidia to Present at Cowen 40th Annual Health Care Conference
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development of products using its proprietary PRINT® technology, today announced that Neal Fowler, Chief Executive Officer of...
Feb 26, 2020 04:30 pm ET
Liquidia to Report 2019 Financial Results and Provide Corporate Update on March 11, 2020
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development of products using its proprietary PRINT® technology, today announced that 2019 financial results will be reported on...
Jan 27, 2020 08:00 am ET
Liquidia Submits New Drug Application for LIQ861 (treprostinil) inhalation powder to U.S. Food and Drug Administration for the Treatment of Pulmonary Arterial Hypertension (PAH)
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development of products using its proprietary PRINT® technology, today announced the submission of its New Drug Application (NDA)...
Jan 24, 2020 09:00 am ET
Liquidia Announces Poster Presentation at the 14th Annual World Congress of the Pulmonary Vascular Research Institute (PVRI)
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT® technology, today announced that it will present a...
Dec 24, 2019 08:30 am ET
Liquidia Technologies Announces $22.4 Million Private Placement
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT® technology, today announced that it has entered...
Nov 13, 2019 07:00 am ET
Liquidia Technologies Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today reported financial results for the quarter ended September 30, 2019, and provided a corporate update. “We continue to...
Nov 06, 2019 08:00 am ET
Liquidia to Report Third Quarter 2019 Financial Results and Provide Corporate Update on November 13, 2019
Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced that third quarter 2019 financial results will be reported on Wednesday, November 13, 2019. The company will...
Nov 01, 2019 08:00 am ET
Liquidia Technologies Appoints Industry Veteran Katie Rielly-Gauvin to Board of Directors
Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced the appointment of Katie Rielly-Gauvin, Vice President of Global Commercial Development at AbbVie, to the...
Sep 25, 2019 04:05 pm ET
Liquidia to Present at Cantor 2019 Global Healthcare Conference
Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the Cantor 2019 Global...
Sep 12, 2019 04:05 pm ET
Liquidia Technologies Appoints Industry Veteran Dr. Joanna Horobin to Board of Directors
Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced the appointment of Joanna Horobin, M.B., Ch.B., to the Company’s Board of Directors (the “Board”) as a Class...
Sep 03, 2019 07:00 am ET
Liquidia to Present at H.C. Wainwright Healthcare Conference
Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the H.C. Wainwright 21st...
Aug 08, 2019 04:05 pm ET
Liquidia to Present at Wedbush PacGrow Healthcare Conference
Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the 2019 Wedbush PacGrow...
Aug 08, 2019 07:00 am ET
Liquidia Technologies Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today reported financial results for the quarter ended June 30, 2019, and provided a corporate update. “Liquidia continues...
Aug 02, 2019 09:00 am ET
Liquidia to Report Second Quarter 2019 Financial Results and Provide Corporate Update on August 8, 2019
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology, today announced that second...
Jun 26, 2019 04:15 pm ET
Liquidia and GSK Restructure Collaboration Agreement
Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology, today...
Jun 05, 2019 04:05 pm ET
Liquidia Announces Clinical Update on INSPIRE; Targeting NDA Filing for LIQ861 in Late 2019
Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today provided an update on the Phase 3 INSPIRE trial and development of LIQ861 for the treatment of pulmonary arterial hypertension (PAH)....
Jun 03, 2019 08:30 am ET
Liquidia to Present at Jefferies Healthcare Conference
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the Jefferies 2019 Healthcare Conference in...
May 22, 2019 04:30 pm ET
Liquidia Appoints Seasoned Biopharmaceutical Industry Executive Dr. Richard Katz as Chief Financial Officer
Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today announced the appointment of Richard D. Katz, M.D., as Chief Financial Officer (CFO). Dr. Katz joins Liquidia with more than 20 years of...
May 14, 2019 04:15 pm ET
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) International Conference 2019
Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today announced that Nicholas Hill, MD, Chief Pulmonary, Critical Care & Sleep Division, Professor of Medicine at Tufts University School of...
May 02, 2019 07:00 am ET
Liquidia Technologies Reports First Quarter 2019 Financial Results and Provides Corporate Update
Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today reported its financial results for the quarter ended March 31, 2019 and provided a corporate update. “Liquidia has started the year...
Apr 23, 2019 04:05 pm ET
Liquidia Technologies to Report First Quarter 2019 Financial Results and Provide Corporate Update on May 2, 2019
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of...
Apr 17, 2019 07:30 am ET
Analysis: Positioning to Benefit within Galmed Pharmaceuticals, Liquidia Technologies, Taylor Devices, Kingstone Companies, Aerpio Pharmaceuticals, and Pingtan Marine Enterprise — Research Highlights
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), Liquidia Technologies, Inc....
Apr 03, 2019 04:30 pm ET
Liquidia Technologies Presents Phase 3 Trial Data for LIQ861 at the ISHLT 39th Annual Meeting & Scientific Sessions
Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of LIQ861, announced today additional detailed safety and exploratory endpoint findings at the...
Apr 02, 2019 08:00 am ET
Liquidia Technologies to Present at Needham Healthcare Conference
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of...
Mar 25, 2019 10:54 am ET
Liquidia Technologies Announces Closing of Offering of Common Stock
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of...
Mar 21, 2019 07:56 am ET
Liquidia Technologies Announces Pricing of Offering of Common Stock
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of...
Mar 18, 2019 04:45 pm ET
Liquidia Technologies Announces Proposed Offering of Common Stock
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of...
Mar 11, 2019 07:00 am ET
Liquidia’s LIQ861 Meets Primary Endpoint in Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension
Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology, today announced top-line...
Feb 26, 2019 07:00 am ET
Liquidia Technologies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of...
Feb 25, 2019 08:31 am ET
Thinking about buying stock in Achieve Life Sciences, Kraft Heinz Co., Liquidia, Roku or Zillow?
NEW YORK, Feb. 25, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACHV, KHC, LQDA, ROKU, and Z.
Feb 13, 2019 04:30 pm ET
Liquidia Technologies to Report 2018 Financial Results and Provide Corporate Update on February 26, 2019
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of...
Jan 07, 2019 07:00 am ET
Liquidia Technologies Reports Positive Interim LIQ861 Safety Data on 109 Patients from Pivotal INSPIRE Trial
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of...
Nov 27, 2018 04:45 pm ET
Liquidia Technologies Provides Leadership Update
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of...
Nov 14, 2018 04:30 pm ET
Liquidia Technologies Recipient of Best-in-Class Public Offering Award at Southeast BIO
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of...
Nov 14, 2018 08:00 am ET
Liquidia Technologies to Present LIQ865 Phase 1a Data at ASRA’s 17th Annual Pain Medicine Meeting
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of...
Nov 14, 2018 07:55 am ET
Analysis: Positioning to Benefit within Harvest Capital Credit, Zynga, Unique Fabricating, SJW Group, Liquidia Technologies, and Rave Restaurant Group — Research Highlights Growth, Revenue, and Consol
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Harvest Capital Credit Corporation (NASDAQ:HCAP), Zynga Inc....
Nov 09, 2018 08:00 am ET
Liquidia Technologies to Present at Jefferies London Healthcare Conference
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of...
Oct 31, 2018 07:00 am ET
Liquidia Technologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of...
Oct 23, 2018 08:00 am ET
Liquidia Technologies to Provide Third Quarter 2018 Corporate Update on October 31, 2018
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of...
Sep 24, 2018 08:00 am ET
Liquidia Technologies Added to Russell 2000®, 3000® and Microcap® Indexes
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of...
Aug 09, 2018 08:00 am ET
Liquidia Technologies to Present at Wedbush PacGrow Healthcare Conference
Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of...
Jul 30, 2018 04:15 pm ET
Liquidia Technologies Announces Closing of Initial Public Offering
Liquidia Technologies, Inc. (the “Company”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced the closing of its initial pub
Jul 25, 2018 07:02 pm ET
Liquidia Technologies Announces Pricing of Initial Public Offering
Liquidia Technologies, Inc. (the “Company”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced the pricing of its

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.